BioAegis Therapeutics

Executive Summary

BioAegis Therapeutics is a private biotech company developing a novel class of therapies centered on plasma gelsolin (pGSN), a naturally occurring human protein that regulates the innate immune response. By restoring pGSN levels, the company aims to treat a range of inflammatory diseases, including sepsis, acute respiratory distress syndrome (ARDS), and other hyperinflammatory conditions. The approach is based on extensive research showing that pGSN depletion correlates with disease severity and poor outcomes, making it a promising target for modulating the immune system. Currently in Phase 1 clinical development, BioAegis is advancing its lead candidate to address high unmet medical needs in critical care settings. The company has generated compelling preclinical data supporting the safety and efficacy of pGSN replacement therapy, and its Phase 1 trial is expected to provide initial proof-of-concept in patients with inflammatory conditions. With a strong intellectual property portfolio and a seasoned management team, BioAegis is well-positioned to attract partnerships or additional funding to accelerate development. Key upcoming milestones include the completion of Phase 1 dose-escalation studies and the initiation of a Phase 2 proof-of-concept trial. If successful, BioAegis could offer a transformative therapy for life-threatening inflammatory diseases, representing a significant opportunity in the immunology space.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical data readout for pGSN in sepsis/ARDS60% success
• TBDStrategic partnership or licensing deal for pGSN platform45% success
• Q2 2027IND acceptance or Phase 2 trial initiation for a second indication50% success